Shared mechanisms of neurodegeneration in alzheimer's disease and parkinson's disease

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Xie, Anmu ^a   Gao, Jing ^a   Xu, Lin ^a   Meng, Dongmei ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SYNUCLEIN; ALUMINUM; ARYLDIALKYLPHOSPHATASE 1; COPPER; CYCLOOXYGENASE 2; GELATINASE B; GLUTATHIONE TRANSFERASE; HEPCIDIN; HUPERZINE A; IRON; LIGAND GATED ION CHANNEL; NICOTINIC RECEPTOR; NORADRENALIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TAU PROTEIN;

ALZHEIMER DISEASE; COGNITION; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENETIC ASSOCIATION; HUMAN; LOCUS CERULEUS; META ANALYSIS (TOPIC); MOLECULAR WEIGHT; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NORADRENERGIC NERVE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; REVIEW; SHY DRAGER SYNDROME; UPREGULATION; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84901806613     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/648740     Document Type: Review

References (67)

1. Oshiro S., Morioka M. S., Kikuchi M., Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Advances in Pharmacological Sciences 2011 2011 8 2-s2.0-84555179169 10.1155/2011/378278 378278
2. Dubois B., Feldman H. H., Jacova C., DeKosky S. T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P. J., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology 2007 6 8 734 746 2-s2.0-34447322271 10.1016/S1474-4422(07)70178-3 (Pubitemid 47058377)
3. Bondi M. W., Serody A. B., Chan A. S., Eberson-Shumate S. C., Delis D. C., Hansen L. A., Salmon D. P., Cognitive and neuropathologic correlates of Stroop Color-Word Test performance in Alzheimer's disease. Neuropsychology 2002 16 3 335 343 2-s2.0-0035996010 10.1037/0894-4105.16.3.335 (Pubitemid 34778899)
4. Tolleson C. M., Fang J. Y., Advances in the mechanisms of Parkinson's disease. Discovery Medicine 2013 15 61 66
5. Lim S.-Y., Lang A. E., The nonmotor symptoms of Parkinson's disease-an overview. Movement Disorders 2010 25 S1 S123 S130 2-s2.0-77953457744 10.1002/mds.22786
6. Moskvina V., Harold D., Russo G., Vedernikov A., Sharma M., Saad M., Holmans P., Bras J. M., Bettella F., Keller M. F., Nicolaou N., Simon-Sanchez J., Gibbs J. R., Schulte C., Durr A., Guerreiro R., Hernandez D., Brice A., Stefansson H., Majamaa K., Gasser T., Heutink P., Wood N., Martinez M., Singleton A. B., Nalls M. A., Hardy J., Owen M. J., O'Donovan M. C., Williams J., Morris H. R., Williams N. M., Analysis of Genome-Wide Association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk. JAMA Neurology 2013 70 10 1268 1276
7. Akhmedova S. N., Yakimovsky A. K., Schwartz E. I., Paraoxonase 1 Met-leu 54 polymorphism is associated with Parkinson's disease. Journal of the Neurological Sciences 2001 184 2 179 182 2-s2.0-0035283113 10.1016/S0022- 510X(01)00439-7 (Pubitemid 32178272)
8. Carmine A., Buervenich S., Sydow O., Anvret M., Olson L., Further evidence for an association of the paraoxonase 1 (PON1) met-54 allele with Parkinson's disease. Movement Disorders 2002 17 4 764 766 2-s2.0-0036651220 10.1002/mds.10172 (Pubitemid 41295021)
9. Leduc V., Théroux L., Dea D., Robitaille Y., Poirier J., Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. European Journal of Neuroscience 2009 30 9 1823 1830 2-s2.0-70350787098 10.1111/j.1460-9568.2009.06983.x
10. Wingo T. S., Rosen A., Cutler D. J., Lah J. J., Levey A. I., Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiology of Aging 2012 33 1 204.e13 204.e15 2-s2.0-81355135329 10.1016/j.neurobiolaging.2010.08.010
11. Allen M., Zou F., Chai H. S., Younkin C. S., Miles R., Nair A. A., Crook J. E., Pankratz V. S., Carrasquillo M. M., Rowley C. N., Nguyen T., Ma L., Malphrus K. G., Bisceglio G., Ortolaza A. I., Palusak R., Middha S., Maharjan S., Georgescu C., Schultz D., Rakhshan F., Kolbert C. P., Jen J., Sando S. B., Aasly J. O., Barcikowska M., Uitti R. J., Wszolek Z. K., Ross O. A., Petersen R. C., Graff-Radford N. R., Dickson D. W., Younkin S. G., Ertekin-Taner N., Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Molecular Neurodegeneration 2012 7 article 13 2-s2.0-84859517209 10.1186/1750-1326-7-13
12. Chapuis J., Moisan F., Mellick G., Elbaz A., Silburn P., Pasquier F., Hannequin D., Lendon C., Campion D., Amouyel P., Lambert J.-C., Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease. Human Molecular Genetics 2008 17 18 2863 2867 2-s2.0-50849091905 10.1093/hmg/ddn183
13. Kim S., Seo J.-H., Suh Y.-H., α -Synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism and Related Disorders 2004 10 1 S9 S13 2-s2.0-1942518751 10.1016/j.parkreldis.2003.11.005 (Pubitemid 38510424)
14. Culvenor J. G., McLean C. A., Cutt S., Campbell B. C. V., Maher F., Jäkälä P., Hartmann T., Beyreuther K., Masters C. L., Li Q.-X., Non-A β component of Alzheimer's disease amyloid (NAC) revisited: NAC and α -synuclein are not associated with A β amyloid. The American Journal of Pathology 1999 155 4 1173 1181 2-s2.0-0032589409 (Pubitemid 29488925)
15. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M., Full length α -synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neuroscience Letters 2000 287 1 65 67 2-s2.0-0034674376 10.1016/S0304-3940(00)01153-8 (Pubitemid 30332379)
16. Yang F., Uéda K., Chen P.-P., Ashe K. H., Cole G. M., Plaque-associated α -synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Research 2000 853 2 381 383 2-s2.0-0342514665 10.1016/S0006-8993(99)02207-6 (Pubitemid 30035240)
17. Koehler N. K., Stransky E., Shing M., Gaertner S., Meyer M., Schreitmuller B., Leyhe T., Laske C., Maetzler W., Kahle P., Celej M. S., Jovin T. M., Fallgatter A. J., Batra A., Buchkremer G., Schott K., Richartz-Salzburger E., Altered serum IgG levels to alpha-synuclein in dementia with Lewy bodies and Alzheimer's disease. PloS ONE 2013 8 e64649
18. Mattsson N., Insel P., Tosun D., Zhang J., Jack C. R. Jr., Galasko D., Weiner M., Effects of Baseline CSF alpha-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease. PloS ONE 2013 8 e85443
19. Korff A., Liu C., Ginghina C., Shi M., Zhang J., alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. Journal of Alzheimer's Disease 2013 36 679 688
20. Li L., Nadanaciva S., Berger Z., Shen W., Paumier K., Schwartz J., Mou K., Loos P., Milici A. J., Dunlop J., Hirst W. D., Human A53T alpha-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons. PloS ONE 2013 8 e85815
21. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E., Lansbury P. T. Jr., Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America 2000 97 2 571 576 (Pubitemid 30070350)
22. Kang J. H., Irwin D. J., Chen-Plotkin A. S., Siderowf A., Caspell C., Coffey C. S., Waligorska T., Taylor P., Pan S., Frasier M., Marek K., Kieburtz K., Jennings D., Simuni T., Tanner C. M., Singleton A., Toga A. W., Chowdhury S., Mollenhauer B., Trojanowski J. Q., Shaw L. M., Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early parkinson disease. JAMA Neurology 2013 70 10 1277 1287
23. Padurariu M., Ciobica A., Lefter R., Serban I. L., Stefanescu C., Chirita R., The oxidative stress hypothesis in Alzheimer's disease. Psychiatria Danubina 2013 25 401 409
24. Kumar Dasappa J., Nagendra H. G., Preferential selectivity of inhibitors with human tau protein kinase gsk3beta elucidates their potential roles for off-target Alzheimer's therapy. International Journal of Alzheimer's Disease 2013 2013 8 809386 10.1155/2013/809386
25. Zimmer E. R., Leuzy A., Bhat V., Gauthier S., Rosa-Neto P., In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Translational Neurodegeneration 2014 3 article 6
26. Lenart N., Szegedi V., Juhasz G., Kasztner A., Horvath J., Bereczki E., Toth M. E., Penke B., Santha M., Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice. PloS ONE 2012 7 e46007
27. Wischik C. M., Harrington C. R., Storey J. M., Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochemical Pharmacology 2014 88 4 529 539 10.1016/j.bcp.2013.12.008
28. Herbert M. K., Eeftens J. M., Aerts M. B., Esselink R. A., Bloem B. R., Kuiperij H. B., Verbeek M. M., CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism & Related Disorders 2014 20 112 115
29. Gonzalez-Dominguez R., Garcia-Barrera T., Gomez-Ariza J. L., Characterization of metal profiles in serum during the progression of Alzheimer's disease. Metallomics: Integrated Biometal Science 2014 6 292 300
30. Raha A. A., Vaishnav R. A., Friedland R. P., Bomford A., Raha-Chowdhury R., The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease. Acta Neuropathologica Communications 2013 1 article 55
31. Huang X. T., Qian Z. M., He X., Gong Q., Wu K. C., Jiang L. R., Lu L. N., Zhu Z. J., Zhang H. Y., Yung W. H., Ke Y., Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease. Neurobiology of Aging 2014 35 5 1045 1054 10.1016/j.neurobiolaging.2013.11.004
32. Raven E. P., Lu P. H., Tishler T. A., Heydari P., Bartzokis G., Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. Journal of Alzheimer's Disease 2013 37 127 136
33. Kruer M. C., The neuropathology of neurodegeneration with brain iron accumulation. International Review of Neurobiology 2013 110 165 194
34. Song N., Jiang H., Wang J., Xie J.-X., Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. Journal of Neuroscience Research 2007 85 14 3118 3126 2-s2.0-35848961208 10.1002/jnr.21430 (Pubitemid 350057367)
35. Rogers J. T., Mikkilineni S., Cantuti-Castelvetri I., Smith D. H., Huang X., Bandyopadhyay S., Cahill C. M., Maccecchini M. L., Lahiri D. K., Greig N. H., The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. Journal of Neural Transmission (Vienna, Austria: 1996) 2011 118 3 493 507 2-s2.0-80051644911 10.1007/s00702-010-0513-5
36. Danzeisen R., Achsel T., Bederke U., Cozzolino M., Crosio C., Ferri A., Frenzel M., Gralla E. B., Huber L., Ludolph A., Nencini M., Rotilio G., Valentine J. S., Carrì M. T., Superoxide dismutase 1 modulates expression of transferrin receptor. Journal of Biological Inorganic Chemistry 2006 11 4 489 498 2-s2.0-33745755199 10.1007/s00775-006-0099-4 (Pubitemid 44012032)
37. Gerlach M., Riederer P., Double K. L., Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease. Parkinsonism and Related Disorders 2008 14 2 S185 S188 2-s2.0-47049099820 10.1016/j.parkreldis.2008.04.028
38. Du F., Qian Z.-M., Zhu L., Wu X. M., Yung W.-H., Tsim T.-Y., Ke Y., L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PloS ONE 2009 4 2 2-s2.0-62349111542 10.1371/journal.pone.0004593 e4593
39. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., Duyckaerts C., Sazdovitch V., Zhao L., Garrick L. M., Nuñez M. T., Garrick M. D., Raisman-Vozari R., Hirsch E. C., Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2008 105 47 18578 18583 2-s2.0-57449092273 10.1073/pnas.0804373105
40. Jin L., Wang J., Zhao L., Jin H., Fei G., Zhang Y., Zeng M., Zhong C., Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011 134 1 50 58 2-s2.0-78650695967 10.1093/brain/awq319
41. Padurariu M., Ciobica A., Hritcu L., Stoica B., Bild W., Stefanescu C., Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neuroscience Letters 2010 469 1 6 10 2-s2.0-72649096229 10.1016/j.neulet.2009.11.033
42. Butterfield D. A., Amyloid β -peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radical Research 2002 36 12 1307 1313 2-s2.0-0036905921 10.1080/1071576021000049890 (Pubitemid 35469517)
43. Zheng L., Roberg K., Jerhammar F., Marcusson J., Terman A., Oxidative stress induces intralysosomal accumulation of alzheimer amyloid β -protein in cultured neuroblastoma cells. Annals of the New York Academy of Sciences 2006 1067 1 248 251 2-s2.0-33744462609 10.1196/annals.1354.032 (Pubitemid 43806332)
44. Varcin M., Bentea E., Michotte Y., Sarre S., Oxidative stress in genetic mouse models of Parkinson's disease. Oxidative Medicine and Cellular Longevity 2012 2012 25 624925 10.1155/2012/624925
45. Vinish M., Anand A., Prabhakar S., Altered oxidative stress levels in Indian Parkinson's disease patients with PARK2 mutations. Acta Biochimica Polonica 2011 58 2 165 169 2-s2.0-79960137032
46. Stefanoni G., Sala G., Tremolizzo L., Brighina L., Ferrarese C., Alpha-Synuclein, Oxidative Stress and Autophagy Failure: Dangerous Liaisons in Dopaminergic Neurodegeneration 2011 InTech
47. Dumont M., Beal M. F., Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology and Medicine 2011 51 5 1014 1026 2-s2.0-80051665640 10.1016/j.freeradbiomed.2010.11.026
48. Yan M. H., Wang X., Zhu X., Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radical Biology & Medicine 2013 62 90 101
49. Autere J., Moilanen J. S., Finnilä S., Soininen H., Mannermaa A., Hartikainen P., Hallikainen M., Majamaa K., Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Human Genetics 2004 115 1 29 35 2-s2.0-2942750228 10.1007/s00439-004-1123-9 (Pubitemid 38787215)
50. Schapira A. H., Jenner P., Etiology and pathogenesis of Parkinson's disease. Movement Disorders 2011 26 6 1049 1055 2-s2.0-79957606041 10.1002/mds.23732
51. Schapira A. H. V., Cooper J. M., Dexter D., Clark J. B., Jenner P., Marsden C. D., Mitochondrial Complex I deficiency in Parkinson's disease. Journal of Neurochemistry 1990 54 3 823 827 2-s2.0-0025254401
52. Lee I. T., Yang C. M., Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochemical Pharmacology 2012 84 581 590
53. Chiurchiù V., MacCarrone M., Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxidants and Redox Signaling 2011 15 9 2605 2641 2-s2.0-80053004011 10.1089/ars.2010.3547
54. Fuller S., Steele M., Münch G., Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles? Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 2010 690 1-2 40 49 2-s2.0-77955281765 10.1016/j.mrfmmm.2009.08.016
55. Hsieh H. L., Yang C. M., Role of redox signaling in neuroinflammation and neurodegenerative diseases. BioMed Research International 2013 2013 18 484613 10.1155/2013/484613
56. Farfara D., Lifshitz V., Frenkel D., Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease: alzheimer's Review Series. Journal of Cellular and Molecular Medicine 2008 12 3 762 780 2-s2.0-44149083565 10.1111/j.1582-4934.2008.00314.x (Pubitemid 351718063)
57. Von Bernhardi R., Eugenín J., Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxidants and Redox Signaling 2012 16 9 974 1031 2-s2.0-84857977037 10.1089/ars.2011.4082
58. Benarroch E. E., The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 2009 73 20 1699 1704 2-s2.0-73449128978 10.1212/WNL.0b013e3181c2937c
59. McMillan P. J., White S. S., Franklin A., Greenup J. L., Leverenz J. B., Raskind M. A., Szot P., Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Research 2011 1373 240 252 2-s2.0-79151475168 10.1016/j.brainres.2010.12.015
60. Szot P., White S. S., Lynne Greenup J., Leverenz J. B., Peskind E. R., Raskind M. A., Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with lewy bodies. Journal of Neuroscience 2006 26 2 467 478 2-s2.0-32544460565 10.1523/JNEUROSCI.4265-05.2006 (Pubitemid 43237111)
61. Braak H., Del Tredici K., Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathologica 2011 121 5 589 595 2-s2.0-79958110883 10.1007/s00401-011-0825-z
62. Braak H., Thal D. R., Ghebremedhin E., Del Tredici K., Stages of the pathologic process in alzheimer disease: age categories from 1 to 100 years. Journal of Neuropathology and Experimental Neurology 2011 70 11 960 969 2-s2.0-80054904670 10.1097/NEN.0b013e318232a379
63. Li L., Cheung T., Chen J., Herrup K., A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death. International Journal of Alzheimer's Disease 2011 2011 10 2-s2.0-81555214518 10.4061/2011/171464 171464
64. Szot P., Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system. Epilepsia 2012 53 supplement 1 61 66
65. Braak H., Rüb U., Del Tredici K., Cognitive decline correlates with neuropathological stage in Parkinson's disease. Journal of the Neurological Sciences 2006 248 1-2 255 258 2-s2.0-33750440804 10.1016/j.jns.2006.05.011 (Pubitemid 44647283)
66. Sethi K., Levodopa unresponsive symptoms in Parkinson disease. Movement Disorders 2008 23 3 S521 S533 2-s2.0-53149118217 10.1002/mds.22049
67. Posadas I., Lopez-Hernandez B., Cena V., Nicotinic receptors in neurodegeneration. Current Neuropharmacology 2013 11 298 314